StockNews.AI
TKNO
StockNews.AI
117 days

Teknova to Report First Quarter 2025 Financial Results on May 8, 2025

1. Teknova to report Q1 financial results on May 8, 2025. 2. Company specializes in critical reagents for novel therapies and diagnostics. 3. Webcast and call scheduled to engage investors regarding financial performance.

4m saved
Insight
Article

FAQ

Why Bullish?

Earnings announcements can drive stock prices as investors speculate on results. Historical data shows positive earnings often lead to price increases.

How important is it?

Upcoming earnings can profoundly influence investor sentiment and stock price. Timing of announcements is critical for market reactions.

Why Short Term?

Immediate reactions often follow earnings announcements, impacting price swiftly. Examples from similar biotech stocks indicate quick market movements post-results.

Related Companies

MRNABNTXNVAX
April 24, 2025 19:51 ET  | Source: Alpha Teknova, Inc. HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, May 8, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to participate in the call, please register for the webcast here to receive a unique PIN number and dial-in information. The webcast will be available for replay on the Company’s website approximately two hours after the event. About TeknovaTeknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in molecular diagnostics, synthetic biology, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies. Investor ContactMatt LowellChief Financial Officermatt.lowell@teknova.com+1 831-637-1100  Media ContactJennifer HenrySenior Vice President, Marketingjenn.henry@teknova.com+1 831-313-1259 This press release was published by a CLEAR® Verified individual.

Related News